We advised AC Immune on the offering

Davis Polk advised AC Immune SA in connection with an SEC-registered at-the-market offering of its common stock for up to an aggregate amount of $80 million. The common stock is listed on the Nasdaq Global Market under the symbol “ACIU.”

Based in Lausanne, Switzerland, AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The company’s two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features 16 therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.

The Davis Polk corporate team included partner Derek Dostal and associates Katie Warshauer and Sakiko Nishida. The tax team included counsel Alon Gurfinkel and associate Kelli A. Rivers. Associates Harrison Perry and Nausherwan Ahmed Aamir provided Investment Company Act advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post